For research use only. Not for therapeutic Use.
Lipoprotein lipase (LPL) mediates the hydrolysis of triglycerides in circulating very low density lipoproteins and chylomicrons. NO-1886 is an LPL activator that increases LPL mRNA and LPL activity in adipose tissue, myocardium, and skeletal muscle. This coincides with an elevation in post-heparin plasma LPL activity and LPL mass in rats. NO-1886 decreases plasma triglyceride concentration and increases plasma high-density lipoprotein cholesterol, resulting in inhibited development of atherosclerotic lesions in coronary arteries and aortas of rats and rabbits.
| Catalog Number | R065546 |
| CAS Number | 133208-93-2 |
| Synonyms | Ibrolipim;Lipoprotein Lipase Activator;LPL Activator;OPF 009 |
| Molecular Formula | C19H20BrN2O4P |
| Purity | ≥95% |
| Storage | -20°C |
| IUPAC Name | N-(4-bromo-2-cyanophenyl)-4-(diethoxyphosphorylmethyl)benzamide |
| InChI | InChI=1S/C19H20BrN2O4P/c1-3-25-27(24,26-4-2)13-14-5-7-15(8-6-14)19(23)22-18-10-9-17(20)11-16(18)12-21/h5-11H,3-4,13H2,1-2H3,(H,22,23) |
| InChIKey | KPRTURMJVWXURQ-UHFFFAOYSA-N |
| SMILES | CCOP(=O)(CC1=CC=C(C=C1)C(=O)NC2=C(C=C(C=C2)Br)C#N)OCC |
| Reference | 1.Kim, M.S.,Wang, Y. and Rodrigues, B. Lipoprotein lipase mediated fatty acid delivery and its impact in diabetic cardiomyopathy. Biochimica et Biophysica Acta 1821(5), 800-808 (2011). |
